ImmuCell (NASDAQ:ICCC) Shares Cross Above 200-Day Moving Average of $5.01

ImmuCell Co. (NASDAQ:ICCC)’s share price passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $5.01 and traded as high as $5.31. ImmuCell shares last traded at $5.29, with a volume of 2,308 shares.

ImmuCell Stock Up 0.8 %

The company has a quick ratio of 0.87, a current ratio of 2.73 and a debt-to-equity ratio of 0.42. The company has a fifty day simple moving average of $5.15 and a 200 day simple moving average of $5.01. The firm has a market capitalization of $41.39 million, a P/E ratio of -7.05 and a beta of 0.60.

ImmuCell (NASDAQ:ICCC) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter. The firm had revenue of $5.10 million during the quarter. ImmuCell had a negative return on equity of 21.79% and a negative net margin of 33.05%.

Institutional Investors Weigh In On ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Mesirow Financial Investment Management Inc. acquired a new stake in ImmuCell Co. (NASDAQ:ICCC) during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned approximately 0.16% of ImmuCell at the end of the most recent quarter. 13.47% of the stock is currently owned by institutional investors and hedge funds.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.